Oculis Highlights Privosegtor Data and Registrational Plans
Oculis will present Phase 2 ACUITY data and outline its PIONEER registrational program in optic neuritis. The company also expects IND clearance for MS relapses in Q4 2026.
Related stories
Japan’s Nikkei Falls 2.1% as AI Spending Concerns Hit Tech Shares
The Nikkei fell as much as 3% before closing down 2.1%, with chip-related shares leading losses amid concerns about the sustainability of spending supporting the AI boom.
M impact | EQUITY | Oct 30, 2026, 07:22 AM UTC
BP Reports Third-Quarter Net Profit Above Expectations
BP reported third-quarter underlying replacement cost profit, which the company describes as net profit, above expectations.
M impact | EQUITY | Oct 30, 2026, 07:21 AM UTC
BP Tops Q3 Profit Expectations on Higher Refining Margins and Trading
H impact | EQUITY | Oct 30, 2026, 07:17 AM UTC
Top S&P 500 Stock Names Implied Volatility
L impact | EQUITY | Oct 30, 2026, 07:12 AM UTC
Bayer Shares Rise 5.0% in Early Frankfurt Trade After Roundup Trial Win
Bayer shares rose 5.0% in early Frankfurt trade after the company won a Roundup weedkiller cancer trial.
M impact | EQUITY | Oct 30, 2026, 07:08 AM UTC
AstraZeneca launches savings programme targeting $1.5 billion in benefits
AstraZeneca said the restructuring programme will support pipeline investment and help keep it on track to generate $80 billion in annual revenue by 2030. It was announced alongsid
M impact | EQUITY | Oct 30, 2026, 07:08 AM UTC